# BioShin

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioshin

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $60M
- Latest round: Series A (Sep 25, 2020)
- Investors on record: 5

## About

Founded in 2019 and based in Shanghai, China, BioShin Limited is a biopharmaceutical company. In September 2020, the firm raised a series A funding for USD 60 million. The company is affiliated with Biohaven Pharmaceutical Holding Company Ltd.

The company's main products include drugs targeting neurological and neuropsychiatric disorders. It has a calcitonin gene-related peptide (CGRP) receptor antagonist and glutamate modulator platform.

## Funding rounds

- Series A, Sep 25, 2020, $60M — OrbiMed Advisors, HBM Partners, Suvretta Capital Management, Cormorant Asset Management, Surveyor Capital

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A
- Suvretta Capital Management — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Surveyor Capital — Series A